Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

JNJ Johnson and Johnson

152,19

0,00 (0,00%)

Pré-mercado

Última atualização: 05:40:51

15 min atrasado - Atualize para Tempo Real

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mai 2025 até Jun 2025

Click aqui para mais gráficos Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Jun 2024 até Jun 2025

Click aqui para mais gráficos Johnson and Johnson.

Notícias Johnson and Johnson

Form 11-K - Annual report of employee stock purchase, savings and similar plans
Segunda, 23 de Junho de 2025 (1 dia atrás) • Edgar (US Regulatory)

Form 11-K - Annual report of employee stock purchase, savings and similar plans
Segunda, 23 de Junho de 2025 (1 dia atrás) • Edgar (US Regulatory)

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
Segunda, 23 de Junho de 2025 (2 dias atrás) • PR Newswire (US)

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Domingo, 15 de Junho de 2025 (1 semana atrás) • PR Newswire (US)

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Sexta, 13 de Junho de 2025 (2 semanas atrás) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 12 de Junho de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 12 de Junho de 2025 (2 semanas atrás) • Edgar (US Regulatory)

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Quinta, 12 de Junho de 2025 (2 semanas atrás) • PR Newswire (US)

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
Quarta, 11 de Junho de 2025 (2 semanas atrás) • PR Newswire (US)

Form 8-K - Current report
Terça, 10 de Junho de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Terça, 10 de Junho de 2025 (2 semanas atrás) • Business Wire

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
Terça, 3 de Junho de 2025 (3 semanas atrás) • PR Newswire (US)

Mais Notícias de Johnson and Johnson

Índice Bovespa

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições